Sclerotherapy and Candida Antigen in Treatment of Common Warts

NANot yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions
Common Wart
Interventions
DRUG

polidacanol 3%

Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany

BIOLOGICAL

candida antigen

delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart

Trial Locations (1)

Unknown

Sohag university hospital, Sohag

All Listed Sponsors
lead

Sohag University

OTHER

NCT06749665 - Sclerotherapy and Candida Antigen in Treatment of Common Warts | Biotech Hunter | Biotech Hunter